UBS Group’s HilleVax HLVX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-34,324
| Closed | -$68.3K | – | 10557 |
|
|
2025
Q2 | $68.3K | Sell |
34,324
-21,487
| -38% | -$39.3K | ﹤0.01% | 7532 |
|
|
2025
Q1 | $80.9K | Buy |
55,811
+9,308
| +20% | +$17.2K | ﹤0.01% | 7206 |
|
|
2024
Q4 | $96.3K | Buy |
46,503
+29,597
| +175% | +$55.6K | ﹤0.01% | 6899 |
|
|
2024
Q3 | $29.8K | Buy |
16,906
+1,738
| +11% | +$4.46K | ﹤0.01% | 7133 |
|
|
2024
Q2 | $219K | Sell |
15,168
-13,693
| -47% | -$188K | ﹤0.01% | 5598 |
|
|
2024
Q1 | $480K | Sell |
28,861
-3,049
| -10% | -$48.8K | ﹤0.01% | 5240 |
|
|
2023
Q4 | $512K | Buy |
31,910
+16,943
| +113% | +$225K | ﹤0.01% | 5086 |
|
|
2023
Q3 | $201K | Sell |
14,967
-299
| -2% | -$4.21K | ﹤0.01% | 5379 |
|
|
2023
Q2 | $262K | Buy |
15,266
+7,248
| +90% | +$112K | ﹤0.01% | 5297 |
|
|
2023
Q1 | $133K | Buy |
8,018
+6,326
| +374% | +$101K | ﹤0.01% | 5693 |
|
|
2022
Q4 | $28.3K | Buy |
1,692
+1,674
| +9,300% | +$30.2K | ﹤0.01% | 7296 |
|
|
2022
Q3 | $0 | Sell |
18
-553
| -97% | -$8.04K | ﹤0.01% | 10580 |
|
|
2022
Q2 | $6K | Buy |
+571
| New | +$6.78K | ﹤0.01% | 8680 |
|
UBS Group's HLVX Position: Q3 2025 in Review
UBS Group sold out of HilleVax (HLVX) in Q3 2025, closing a stake of 34,324 shares — an estimated $68.3K sold.
UBS Group first reported a position in HLVX in Q2 2022 and held it in 13 quarters. The position peaked at $512K in Q4 2023. 1 fund tracked by Wall St. Rank holds HLVX as of Q3 2025.
- UBS Group reported no remaining HilleVax position as of Q3 2025 after selling out during the quarter.
- UBS Group sold 34,324 HilleVax shares in Q3 2025, an estimated $68.3K.
- UBS Group first reported a position in HilleVax in Q2 2022 and held it in 13 quarters.
- UBS Group's HilleVax position peaked at $512K in Q4 2023.
- 1 fund tracked by Wall St. Rank held HilleVax as of Q3 2025.
Based on UBS Group's 13F filing for Q3 2025, filed 13 Nov 2025.